Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer (Q83145997)
Jump to navigation
Jump to search
scientific article published on 27 December 2011
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer |
scientific article published on 27 December 2011 |
Statements
Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer (English)
Ignace Vergote
Jan Lubinski
Ursula Matulonis
Stan B Kaye
Joo Ern Ang
Charlie Gourley
Beth Y Karlan
Amit Amnon
Katherine M Bell-McGuinn
Lee-May Chen
Michael Friedlander
Tamar Safra
Mark Wickens
Elizabeth S Lowe
James Carmichael
27 December 2011